BioSpace News Archive

Business

Aptevo Therapeutics Reports Third Quarter 2017 Financial Results

Aptevo had cash, cash equivalents, and short-term investments as of September 30, 2017 totaling $107.2 million, including $10.4 million in restricted cash related to Aptevo’s borrowing facility and company credit cards.

November 10, 2017

·

14 min read

Drug Development

Alexo Therapeutics Presents Preliminary Results From ALX148 Phase I Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma

Preliminary results from the single agent portion of the trial (NCT03013218) showed that ALX148 is generally well tolerated in patients with advanced malignancy, with no dose-dependent impact on normal blood cells.

November 10, 2017

·

3 min read

Deals

Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.

Valeant will use approximately $180M of the net proceeds from the sale to repay term loan debt under its Senior Credit Facility.

November 10, 2017

·

3 min read

Pharm Country

Bristol-Myers Squibb Release: U.S. Food and Drug Administration Expands Approval of Sprycel (Dasatinib) to Include Treatment of Children With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Bristol-Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel (dasatinib) tablets to include the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).

November 10, 2017

·

21 min read

BioForest

Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting

The findings will be presented on Friday, November 10, in a poster session titled “Immune Modulation, Cytokines, and Antibodies” [#P343] at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting in National Harbor, MD.

November 10, 2017

·

5 min read

Policy

Vertex Receives CHMP Positive Opinion for ORKAMBI (Lumacaftor/Ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 6-11 With Two Copies of the F508del Mutation in the European Union

In other countries, Vertex will begin the country-by-country reimbursement process following Marketing Authorization.

November 10, 2017

·

8 min read

Business

BioSpecifics Technologies Corp. Reports Third Quarter 2017 Financial Results

Total revenue for the third quarter ended September 30, 2017 was $6.5M compared to $6.9M for the same period in 2016.

November 10, 2017

·

18 min read

Business

ERS Genomics and Cellecta Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services

Financial details of the agreement were not disclosed.

November 10, 2017

·

3 min read

Biotech Beach

Ontario Health Technology Advisory Committee Recommends Public Funding for Second Sight’s Argus II Retinal Prosthesis System

Second Sight Medical Products announced that the Argus II Retinal Prosthesis System (“Argus II”) has been recommended for public funding by the Ontario Health Technology Advisory Committee (OHTAC) of Health Quality Ontario.

November 10, 2017

·

6 min read

Biotech Bay

Veeva Systems Release: Industry Research Shows 97% of Companies to Increase Use of Real-World Patient Data for More Accurate Decision-Making

November 10, 2017

·

6 min read